-The Hindu Business Line   The CAG report details how these have neither helped industrial development nor boosted the economy Nearly a decade after the Special Economic Zones Act was brought into force, it is evident that the move has not helped industrial development. After examining SEZs in terms of background and objectives, fiscal incentives and facilities, approval process and administration, as well as life cycle, State-wise distribution and overall performance, parts of a...

-Vikalp Once again, India is under pressure from the US to revise its patent law. Anyone familiar with the activities of the United States Trade Representatives (USTR) would know that this is nothing new. It has been among the USTR's primary mandates to use trade restrictions in order to persuade (to put it mildly) countries to strengthen their IPR laws. There is, however, a qualitative difference between the actions it has...

-The Indian Express With the positive intent and progressive action from the new government, the country is excited about entering a new era of growth & revolutionary transformation. This can happen faster and more effectively if the whole ecosystem is geared for it. And most important component of the ecosystem are the people, who are the primary beneficiaries as well as the key catalysts to stimulate this growth and transformation. Hence,...

-Livemint The development economist on the Modi government's initiatives and his stand on them, and MGNREGS The Narendra Modi-led government should consider replacing inefficient subsidies with a basic monthly income for all citizens, says Pranab Bardhan , emeritus professor of economics at the University of California at Berkeley. Bardhan, who recently sparred with economists Jagdish Bhagwati and Arvind Panagariya in a debate over the Mahatma Gandhi National Rural Employment Guarantee Scheme (MGNREGS),...

-The Times of India NEW DELHI: The government's price control measure for essential medicines has had an unexpected fallout - several of these drugs, including those for treatment of chronic ailments such as high uric acid levels, diabetes and acne, are either in short supply or have gone missing from chemist shops. Among the drugs facing shortage are Zyloric (prescribed for uric acid control), Ocid (acidity), CCM (calcium supplement) and Etroxin (a...